Wall Street investors pour money into developing new psychedelic treatments for mental illnesses; extreme temperature fluctuations around the country can pose health risks; Moderna and Merck's combination skin cancer treatment receives breakthrough designation from the FDA.
Wall Street Supports Psychedelic Drug Venture
Tens of millions of dollars are being invested into psychedelic drugs that supporters say could treat mental illness for much less than the cost of better-known traditional treatments, reports The Wall Street Journal. Venture capitalists invested $40 million with Transcend Therapeutics Inc in January to create a post-traumatic stress disorder treatment, with CEO Blake Mandell noting this would need half the amount of therapy as MDMA (ecstasy). Other companies have following suit; both Gilgamesh Pharmaceuticals Inc and Lusaris Therapeutics Inc have raised approximately $100 million since November. Traditional psychedelics cost more for reasons like needing therapists to administer medication and psychotherapy before and after administration.
Weather Extremes Can Worsen Health
Major fluctuations in temperature can worsen human health problems, especially for people currently dealing with medical conditions, said The Washington Post. The extreme changes in temperature being experienced across the United States can worsen allergies, potentially cause infections, and exacerbate heart disease, according to experts. Especially with the latter, rapid temperature changes can be detrimental to heart health, with heat stressing the body and causing the release of harmful stress hormones and cold leading to hypothermia, said Aaron Bernstein, MD, MPH, interim director of the Center for Climate, Health, and the Global Environment at the Harvard T.H. Chan School of Public Health.
FDA Grants Breakthrough Designation to Moderna/Merck Skin Cancer Treatment
Moderna and Merck have announced that Moderna's experimental personalized mRNA skin cancer vaccine combined with Merck's Keytruda (pembrolizumab) has secured a breakthrough therapy designation from the FDA as a supplementary treatment for high-risk patients, reported Reuters. The designation is based on midstage study data that demonstrate that the combination reduced the risk of skin cancer recurrence or death by 44% compared with Keytruda alone.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More